SanBio (SNBIF) Stock Price, News & Analysis

Company Overview

SanBio Inc. is a clinical‐stage biotechnology company headquartered in Tokyo, Japan, that specializes in the development of regenerative cell therapies for neurological conditions. The company’s proprietary platform leverages modified human bone marrow‐derived mesenchymal stem cells designed to support tissue repair and functional recovery in the central nervous system. SanBio’s lead investigational product, SB623, has been studied in clinical trials targeting chronic motor deficits resulting from stroke, traumatic brain injury and cerebral palsy.

Founded in 1999, SanBio operates research and development facilities in Japan and maintains a subsidiary in the United States to advance its global clinical programs. The company has conducted multiple Phase II studies of SB623 in the U.S., reporting encouraging safety and exploratory efficacy signals. SanBio has also entered a collaboration with Teijin Limited to support the development and potential commercialization of its cell therapy candidates in select Asian markets.

In addition to its SB623 program, SanBio is exploring next-generation cell therapy approaches and pursuing partnerships aimed at extending its regenerative medicine portfolio. With a focus on neurological repair, the company’s development strategy emphasizes rigorous clinical evaluation, regulatory engagement and commercialization planning in key geographies where unmet medical needs persist.

Key Stats

• Today's Range: C$14.28 to C$14.28
• 50-Day Range: C$11.32 to C$15.00
• 52-Week Range: C$4.65 to C$15.00
• Volume: N/A
• Average Volume: 461 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SNBIF Stock Analysis - Frequently Asked Questions

How have SNBIF shares performed this year?

SanBio's stock was trading at C$4.65 at the beginning of 2025. Since then, SNBIF stock has increased by 207.1% and is now trading at C$14.28.

How do I buy shares of SanBio?

Shares of SNBIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SNBIF
• CIK: N/A
• Web: www.sanbio.jp
• Phone: 81 3 6264 3481
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A